Download - 4-3 Documentation Quality
-
7/29/2019 4-3 Documentation Quality
1/55
Jakarta, October 2009
Requirements on documentation of API and FPPquality and evaluation process
Presented byRutendo Kuwana
Prequalification of Medicines Programme
QSM / EMP / HSS
-
7/29/2019 4-3 Documentation Quality
2/55
Jakarta, October 2009
WHO Reference text for Multisource
(Generic) products / Definitions
Active Pharmaceutical Ingredient (API)
A substance or compound that is intended to be used in the manufacture of a
pharmaceutical product as a therapeutically active compound (ingredient)
Pharmaceutical Product
Any preparation for human or veterinary use that is intended to modify or
explore physiological systems or pathological states for the benefit of therecipient.
Finished Pharmaceutical Product (FPP)
A product that has undergone all stages of production, including packaging in
its final container and labelling.
-
7/29/2019 4-3 Documentation Quality
3/55
Jakarta, October 2009
Reference texts
Prequalification quality guidelines for dossier submission
Guideline on submission of documentation for prequalification of multi-
source (Generic) Finished Pharmaceutical Products (FPPs) used intreatment of HIV/AIDS, Malaria and Tuberculosis (Main Generic guide with8 annexes) [under revision]
Supplement 1 : Dissolution testing
Supplement 2 : Extension of the WHO list of stable APIs (not easilydegradable)
Guidelines for registration of fixed-dose combination medicinal products
Guideline on Active Pharmaceutical Ingredient Master File (APIMF)Procedure
Guidance on variations to a prequalified dossier
ICH notes for guidance (When WHO or PQ guidelines silent)
Prequalification of Generic products approved by Stringent RegulatoryAuthorities (SRAs) NEW
Requalification Draft not finalised and not yet adopted
-
7/29/2019 4-3 Documentation Quality
4/55
Jakarta, October 2009
Guidelines for Product dossier /Quality
Main Generic guide
Guideline on Submission of Documentation for Prequalification of
Multisource (Generic) Finished Pharmaceutical Products (FPPs) Used inthe Treatment of HIV/AIDS, Malaria and Tuberculosis [under revision]
Annex 1 - Model Certificate of a Pharmaceutical Product
Annex 2 - Model Batch Certificate of Pharmaceutical Product
Annex 3 - Model Stability Report of Active Pharmaceutical Ingredient (API)
Annex 4 - Model Stability Report of Capsules/Tablets
Annex 5 - Suggested Structure of the Summary of Product Characteristics(SmPC)
Annex 6 - Suggested Structure of the Package Information Leaflet (PIL)
Annex 7 - Presentation of Bioequivalence Trial Information (BTIF)
Annex 8 - Presentation of Pharmaceutical Quality Information (PQIF)
http://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX1.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFpps_08_2005_ANNEX2.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX3.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX4.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX5.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX6.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX7.dochttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX8.dochttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX8.dochttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX8.dochttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX7.dochttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX7.dochttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX6.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX6.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX5.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX5.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX4.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX4.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX3.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX3.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFpps_08_2005_ANNEX2.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFpps_08_2005_ANNEX2.pdfhttp://healthtech.who.int/pq/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX1.pdf -
7/29/2019 4-3 Documentation Quality
5/55
Jakarta, October 2009
Assessment Process - Quality
Submission of application
PQIF, Dossier, BTIF
Screening (Internal)
Acceptance
Pre Assessment Screening
Assessment
Report
Additional data
Prequalification LoPQ
Requalification
-
7/29/2019 4-3 Documentation Quality
6/55
Jakarta, October 2009
Quality dossier / Section 1
Information on the FPP
1.1. Details of the Product
- Name, dosage form and strength of the product
- Approved generic name (INN)
- Visual description of the FPP
- Visual description of the packaging
1.2. Samples to be provided (for visual examination of assessors and
comparison with the SPC and PIL)
1.3. Regulatory situation in Member States / list countries
- Countries where a MA has been issued
- Countries where a MA has been withdrawn
- Countries where a Marketing Application has been rejected, deferred
-
7/29/2019 4-3 Documentation Quality
7/55
Jakarta, October 2009
Quality dossier / Section 2
Active Pharmaceutical Ingredient
(API)
-
7/29/2019 4-3 Documentation Quality
8/55
Jakarta, October 2009
Quality dossier / Section 2
Active Pharmaceutical Ingredient (API)
Scientific data on the API can be submitted using
following ways and order of preference
A valid Certificate of Suitability(CoS) or CEP, latest version, with
all its annexes issued by EDQM
AnAPIMF(Active Pharmaceutical Ingredient Master File) submittedby the API manufacturer, containing the whole information requested
in section 2 and presented in CTD format (see APIMF guideline)
Completesubmission ofdata requested in Section 2
-
7/29/2019 4-3 Documentation Quality
9/55
Jakarta, October 2009
Quality dossier / Section 2
of PQIF - Active Pharmaceutical Ingredient (API)
2.1. Nomenclature
2.2. Properties of the API
2.3. Site(s) of manufacture
2.4. Route(s) of synthesis
2.5. Specifications
2.6. Container- closure system
2.7. Stability testing
-
7/29/2019 4-3 Documentation Quality
10/55
Jakarta, October 2009
CTD Structure of API Sections
2.3.S DRUG SUBSTANCE
2.3.S.1 General Information
2.3.S.2 Manufacture
2.3.S.3 Characterisation
2.3.S.4 Control of Drug Substance
2.3.S.5 Reference Standards or Materials
2.3.S.6 Container Closure System
2.3.S.7 Stability
-
7/29/2019 4-3 Documentation Quality
11/55
Jakarta, October 2009
2.3.S DRUG SUBSTANCE
2.3.S.1 General Information
2.3.S.1.1 Nomenclature
Include INN, compendial name, chemical name(s),company/laboratory code, other non-proprietary names eg USAN,JAN, BAN and Chemical Abstracts Service (CAS) registry number.
2.3.S.1.2 Structure
Include structural formula with relative and absolutestereochemistry, molecular formula, and the relative molecularmass.
2.3.S.1.3 General Properties
Physicochemical and other relevant properties of the API.
-
7/29/2019 4-3 Documentation Quality
12/55
Jakarta, October 2009
2.3.S.2 Manufacture
Information on the manufacturer;
A brief description of the manufacturing process
(including, for example, starting materials, reagents,
solvents, critical steps, and reprocessing) and the
controls intended to result in the routine and consistentproduction of API.
A flow diagram;
A description of the Source and Starting Material and rawmaterials used in the manufacture of the API;
-
7/29/2019 4-3 Documentation Quality
13/55
Jakarta, October 2009
2.3.S.2 Manufacture Contd
A discussion of the selection and justification of criticalmanufacturing steps, process controls, and acceptancecriteria. Discuss critical process intermediates;
A description of process validation and/or evaluation.
A brief summary of major manufacturing changes madethroughout development and conclusions from theassessment used to evaluate product consistency. TheQOS should cross-refer to the non-clinical and clinical
studies that used batches affected by thesemanufacturing changes.
-
7/29/2019 4-3 Documentation Quality
14/55
Jakarta, October 2009
2.3.S.3 Characterisation
A summary of the interpretation of evidence of structureand isomerism.
When an API is chiral, it should be specified whether
specific stereoisomers or a mixture of stereoisomers have
been used in the nonclinical and clinical studies, and
information should be given as to the stereoisomer of the
API that is to be used in the final product intended for
marketing.
-
7/29/2019 4-3 Documentation Quality
15/55
Jakarta, October 2009
2.3.S.3 Characterisation Contd:
Impurities
Summary of the data on potential and actual impurities arising fromthe synthesis, manufacture and/or degradation, and should
summarise the basis for setting the acceptance criteria for
individual and total impurities.
Summary of the impurity levels in batches of the API used in the
non-clinical studies, in the clinical trials, and in typical batches
manufactured by the proposed commercial process. The QOS
should state how the proposed impurity limits are qualified.
A tabulated summary, with graphical representation, where
appropriate should be included.
-
7/29/2019 4-3 Documentation Quality
16/55
Jakarta, October 2009
2.3.S.4 Control of Drug Substance
A summary of the specification(s), the analyticalprocedures, and validation should be included.
A tabulated summary of the batch analyses.
-
7/29/2019 4-3 Documentation Quality
17/55
Jakarta, October 2009
2.3.S.5 Reference Standards or Materials
Information on primary and working standards of the APIand specified impurities.
-
7/29/2019 4-3 Documentation Quality
18/55
Jakarta, October 2009
2.3.S.6 Container Closure System
A brief description and discussion of the primary andsecondary packaging components.
-
7/29/2019 4-3 Documentation Quality
19/55
Jakarta, October 2009
2.3.S.7 Stability
This section should include a summary of the studiesundertaken (conditions, batches, analytical procedures)
and a brief discussion of the results and conclusions, the
proposed storage conditions, retest date or shelf-life.
The post-approval stability protocol should be included.
-
7/29/2019 4-3 Documentation Quality
20/55
Jakarta, October 2009
Quality dossier / Section 2
Active Pharmaceutical Ingredient (API)
PQ dossier section 2CTD2.1 Nomenclature
2.2 Properties of API (s)
S.1 General Information- Nomenclature
- Structure
- General Properties
2.3 Site(s) of Manufacture
2.4 Route(s) of synthesis- API not described in pharmacopoeia
- Specifications of raw materials and intermediates used in
synthesis
- API described in a pharmacopoeia
S.2 Manufacture- Manufacturer- Description of manufacturing process
- Control of materials- Control of critical steps and intermediates
- Process validation
- Manufacturing process development
S.3 Characterisation- Elucidation of structure
- Impurities
2.5 SpecificationsS.4 Control of Drug Substance
S.5 Reference Standards or Materials
2.6 Container Closure System
2.7 Stability testing
S.6 Container Closure System
S.7 Stability testing
-
7/29/2019 4-3 Documentation Quality
21/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product
(FPP)
-
7/29/2019 4-3 Documentation Quality
22/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)3.1. Manufacturing and marketing authorization
3.2. Pharmaceutical development
3.3. Formulation
3.4. Sites of manufacture
3.5. Manufacturing process
3.6. Manufacturing process controls of Critical steps and intermediates
3.7. Process validation and Evaluation
3.8. Specifications for excipients
3.9. Control of the FPP
3.10. Container/closure system (s) and other packaging
3.11. Stability testing
-
7/29/2019 4-3 Documentation Quality
23/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.12. Container labelling
3.13. Product information for health professionals
3.14. Patient information and package leaflet
3.15. Justification for any differences to the product in the country
ORcountries issuing the submitted WHO-type certificate(s)
-
7/29/2019 4-3 Documentation Quality
24/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.1. Manufacturing and Marketing Authorization
- Valid manufacturing authorization for pharmaceuticalproduction including the pharmaceutical form applied for
- Marketing authorization to demonstrate the product isregistered / licensed in accordance with national requirements
3.2. Pharmaceutical development
The aim is to build a quality product by design.
-
7/29/2019 4-3 Documentation Quality
25/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.2. Pharmaceutical development
The section should contain information on the development studiesconducted to establish that
the dosage form,
the formulation, the manufacturing process,
the container closure system,
microbiological attributes and
storage and usage instructions
are appropriate for the purpose specified in the dossier.
-
7/29/2019 4-3 Documentation Quality
26/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.2. Pharmaceutical development (pre-formulation)
Physico-chemical characteristics of the APIs
solubility (composition)
water content (stability)
hygroscopicity (stability)
particle size (solubility, bioavailability, suspension properties,
stability )
polymorphism (solubility, bioavailability, stability)
Data obtained from literature : Books, Journals, International Pharmaceutical
Abstracts, Chemical Abstracts, Analytical Abstracts, Internet
Experimental data (if necessary)
-
7/29/2019 4-3 Documentation Quality
27/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.2. Pharmaceutical development (choice of excipients)
Intended function of each excipient
Criteria compatibility of excipients with API(s),
characteristics of the excipients (water content, particle size, flowability,density, rheological behavior)
Particularly : other non active constituents (lowest acceptableconcentration to be chosen e.g. concentration of parabens aspreservatives)
Experimental data needed.
-
7/29/2019 4-3 Documentation Quality
28/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.2. Pharmaceutical development (choice of the manufacturing
process)
Parameters : characteristics of the APIs, dosage form, composition. .
Rational behind the choice (e.g. why a non over kill process as a sterilisationprocess instead of terminal sterilisation in final container)
Justification of the overage (if any)
Identification of the critical steps
In Process Control (IPC)
Selection and optimisation of manufacturing process
Q li d i / S i 3
-
7/29/2019 4-3 Documentation Quality
29/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.2. Pharmaceutical development (dissolution testing)
To study dissolution operating conditions (media, pH, rotation, )
To develop a discriminatory dissolution method
Comparative dissolution testing is a tool, mandatory in developmentpharmaceutics section of the dossier in PQ, See Supplement 1
Help in selection of the formulation
- compare formulation(s) with innovator product,
- a basic strategy in development to maximize thechances of bioequivalence
Comparison of pivotal batches to commercial batches/ post-approval changes
Setting of dissolution specifications
Q li d i / S i 3
-
7/29/2019 4-3 Documentation Quality
30/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)3.2. Pharmaceutical development (comparative dissolution testing)
1. Three media - 900 ml or less - all at 37C Buffer pH 1.2 or0.1M HCl
Buffer pH 4.5
Buffer pH 6.8
Water may be usedadditionally (not instead of)
2. Paddle at 50 orbasket at 100 rpm
3. Twelve units of each product in all 3 media
4. Dissolution samples collected at short intervals, e.g. 10, 15, 20, 30, 45 and 60 minutes Analyse samples for all APIs, when applicable
5. Calculate similarity factor f2
-
7/29/2019 4-3 Documentation Quality
31/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.2. Pharmaceutical development (details of batches
studied)
Provide a summary of development of the FPP from pre-
formulation to production scale.
Provide a comparison of formulas (tabulated form) of: bio-batche(s) (clinical / bioequivalence),
development batches,
stability batches,
batches for validation/production
-
7/29/2019 4-3 Documentation Quality
32/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.2. Pharmaceutical development (choice of formulation
and compatibility)
Compatibility of APIs with the excipients
Compatibility of APIs between each other in case of fixed dose
combinations
-
7/29/2019 4-3 Documentation Quality
33/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.3. Formulation
Formula in tabulated form for :
Administration unit (e.g. one tablet),
Typical batch
- Precise any overage,
- Precise quantity adjustment of the API,
- Precise q.s. for excipient.
Excipients :
State function (e.g. lubricant, disintegrant),
Precise technical grade (e.g. micronised, purified water),
describe also those removed during process (e.g. water),
Describe also those not always added (e.g. acid & alkali for pH adjustment,
Capsule shells, inked imprints on dosage form, Also gas (inert atmosphere).
Q / S 3
-
7/29/2019 4-3 Documentation Quality
34/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.4. Manufacturing sites
Name and street address of each facility where any aspect ofmanufacture occurs including production, sterilisation,packaging and quality control include Units and/or Blocks
Include any alternative manufacturers
Certificate issued by the Competent DRA according to WHOCertification scheme for each site where a major step ofmanufacturing is performed
Submit a valid GMP certificate
Q lit d i / S ti 3
-
7/29/2019 4-3 Documentation Quality
35/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.5. Manufacturing process (cont.)
Flow chart with indication of each step showing where materials
enter the process. Indication of critical steps and in-process
controls
Description of manufacturing/packaging including
Scale
Equipment by type (e.g. tumble blender) & working capacity
Process parameters for steps, (e.g. time, temperature, pH)
Environmental conditions, e.g. relative humidity for hygroscopic
FPPs., area class for sterile FPPs
Steps of the process
Alternative methods
Q lit d i / S ti 3
-
7/29/2019 4-3 Documentation Quality
36/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.5. Manufacturing process (cont.)
Proposal for reprocessing justified with data.
Copy of master formula.
Batch manufacturing record real batch.
Sterile products sterilisation steps and/or aseptic procedures.
Description of in-process tests including plan of sampling and acceptance
limits.
Data for 3 full scale batches to support achievement of predetermined
specifications.
Q lit d i / S ti 3
-
7/29/2019 4-3 Documentation Quality
37/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.6. Manufacturing Process Controls of Critical steps and
Intermediates
Identification of critical steps with test methods and justified
acceptance criteria
Information on quality of isolated intermediates, test methods
and justified acceptance criteria to control them
Q lit d i / S ti 3
-
7/29/2019 4-3 Documentation Quality
38/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.7. Process Validation and Evaluation
Validation mandatory for processes including a critical step
The aim is to show that critical steps are under control and lead continuously tothe desirable quality
Examples of critical steps (list non exhaustive) mixing,
coating,
granulation,
emulsification,
non-standard sterilisation
Q lit d i / S ti 3
-
7/29/2019 4-3 Documentation Quality
39/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.7. Process Validation and Evaluation (details on 3 first production batches)
Batches. batch number
. batch size
. place and date of manufacture
. batch number of API(s)
. yield
. batch purpose (validation, stability, clinical trial )
Process. equipment
. process parameters
. validation protocol.
Results
. critical steps
. in process control
. finished product
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
40/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.7. Process Validation and Evaluation
Concurrent validation carried out during normal production on
the first 3 production batches
OR
For well-established processes
process data, in-process controls and quality controls on a total
of 10- 25 batches to present a statistically significant picture
Q lit d i / S ti 3
-
7/29/2019 4-3 Documentation Quality
41/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.7. Process Validation and Evaluation
If validation data (on production scale batches) are not
available submit
validation protocol,
commitment that validation report will be submitted later for
evaluation,
commitment that data will be available in case of inspection,
commitment that WHO will be informed of any significant
deviation.
Q lit d i / S ti 3
-
7/29/2019 4-3 Documentation Quality
42/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.7. Process Validation and Evaluation
Validation protocol should include
brief description of the process with summary of critical steps and parameters to befollowed during validation,
specifications of the FPP at release,
details of analytical procedures and limits,
sampling plan,
unifromity of dosage units essential for FDCs,
proposed timeframe
Validation report when submitted should includeresults for each batch, certificates of analysis, batch production records,report on unusual findings, modifications, observations and conclusions
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
43/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)3.8. Specifications for excipients
- Non pharmacopoeial substances- Details for manufacturing process,- Specifications (description of procedures and acceptance criteria)- Stability data- Cross-reference to non-clinical (toxicological)- clinical data for safety aspects- Certificates of analyses
- Pharmacopoeial excipients
Copy of the pharmacopoeial monograph used for control + certificates of analysis
- For excipients of animal, human, microbial origin
- TSE (Transmissible Spongiform Encephalopathy) risks and viral safety should beaddressed- TSE CEP preferred
Permitted colorantsare those allowed in UE, USA and Japan
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
44/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.9. Control of the FPP
2 sets of specifications are possible: at release and at the end of shelf-life(list of attributes non exhaustive)
Description of the FPP /appearance
Identification of API
Assay of API: 5% of the label claim at release and 10% at the end of shelf-life
Degradation products
Pharmaceutical tests e.g. dissolution, disintegration (where applicable)
Uniformity of dosage units (mass or content)
Identification of colorants, identification and assay of anti-oxidants, chemical
preservatives
Microbial contamination, Sterility, bacterial endotoxins
Q lit d i / S ti 3
-
7/29/2019 4-3 Documentation Quality
45/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.9. Control of the FPP (cont.)
Monographs of Ph. Int., USP, BP are acceptable for the FPP +
complementary tests
If non-pharmacopoeial FPP, note for guidance Q6A applicable
Description of all analytical procedures in details if not described in a
pharmacopoeial monograph
Validation of analytical methods and/or demonstration of applicability for
pharmacopoeial methods
Batch analyses for 3 lots with details of each lot (batch no, size, date of
manufacture, use of batch)
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
46/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.10. Container-closure system
Discussion on the choice of container
Choice of the materialProtection against light and humiditycompatibility/interaction of materials in contact with dosage formSafety of materials used
Detailed description of the container
Specifications of the container with dimensions and drawingsSpecifications of materials in contact with FPPComposition of these materials, compliance with pharmacopoeiaIdentification of components e.g. IR for plastic materials
Description of the secondary packaging
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
47/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.11. Stability testing
The purpose of stability testing is to provide evidence on how the
quality of a FPP varies with time under the influence of a variety
of environmental conditions such as temperature, humidity
and light and to establish a shelf-life for the FPP, to determine
the storage conditions and the in-use stability.
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
48/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.11. Stability testing
Lots included in the study: 1 production batch and 2 of pilot scalemanufactured according to the process described in the dossier3 Pilotscale batches are acceptable(exception for 2nd line TB products: 2 pilot batches)
Pilot scale batch for solid dosage forms is 10% of production scale or100 000 whichever is greater
Parameters susceptible to change over storage should be followed:
. Organoleptic properties
. Assay of each API: 10% of the label claim possible at the end of shelf-life
. Assay of degradation products
. Assay of antioxidants and chemical preservatives, check also for their efficacy
. Dissolution testing (limits should remain unchanged to release)
. Microbial contamination, sterility, bacterial endotoxins
In-use stability data (if applicable)
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
49/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.11. Stability testing
Study should be performed in the claimed commercial packaging (container-closure)
Storage conditions and frequency of testing according to WHO stability guideline inTRS 953
Minimum stability data to be submitted at time of submission:
Long term 12 months or 6 months or 3 months (as appropriate according toSupplement 2 to the Main Generic guide and exception for TB 2nd line
products) 6 months intermediate 30C/65% RH
6 months accelerated 40C/75% RH
Unless otherwise justified, 30C / 75% RH is the recommended storage condition forPrequalification
Definition of "significant change" in WHO stability guide is the same as ICH Q1A (R2)
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
50/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.11. Stability testing
Case of products packed in semi-permeable containers foreseen (liquiddosage forms susceptible to loss of solvent or water loss in low relativehumidity condition). The storage condition will be long term ICH 25C / 40%RHOR30C/35% RH and accelerated 40C/25% RH
Extrapolation of data to accord a longer shelf-life possible according to ICHQ1E + Supplement 2 in condition of commitments
Supplement 2: tentative 2 year re-test period and /or shelf-life may beaccorded to APIs and corresponding solid forms (tablets and capsules)listed in Supplement 2 based only on 6 months accelerated data and 6months long term data
Long term stability should anyhow be followed to cover the whole shelf-life
accorded
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
51/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.12. Container labellingOuter packaging : Where no outer packaging, on immediatepackaging, e.g. HDPE bottle.
Labelling should include at least the following :
The name of the FPP.
Method of administration.
A list of API(s) (using INNs if applicable) showing the amount of each present in adosage unit, and a statement of the container, e.g. number of dosage units, weight or
volume. List of excipients known to be a safety concern for some patients, e.g. lactose, gluten,
metabisulfites, parabens, ethanol, or tartrazine.
Instruction on use.
The batch number assigned by the manufacturer.
The expiry date in an uncoded form.
Storage conditions or handling precautions that may be necessary.
Directions for use, and any warnings or precautions that may be necessary.
The name and address of the manufacturer, company or person responsible for placingthe product on the market.
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
52/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.12. Container labelling
Blisters and stripsshould include, as a minimum, the following
information
Name, strength and pharmaceutical form of the FPP
Name of the manufacturer, company or person
responsible for placing the product on the market
The batch number assigned by the manufacturer
The expiry date in an un-coded form
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
53/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.13. Product information for Health Professionals
Summary of product characteristics (SmPC)
Aimed at medical practitioners and health professionals Changes to SmPC to be approved by WHO
See Annex 5 of the main generic guide
Quality dossier / Section 3
-
7/29/2019 4-3 Documentation Quality
54/55
Jakarta, October 2009
Quality dossier / Section 3
Finished Pharmaceutical Product (FPP)
3.14. Patient information and package leaflet
Copy of the patient information leaflet (PIL)
In conformance with SmPC
See Annex 6 of the main Generic guide
-
7/29/2019 4-3 Documentation Quality
55/55
Thank youfor your attention